About
Mivax Therapeutics, Inc. is an early-stage, stealth biotechnology company incorporated in Delaware and based in San Francisco, and a resident company of the MBC BioLabs incubator.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Mivax Therapeutics
Mivax Therapeutics, Inc. is an early-stage, stealth biotechnology company incorporated in Delaware and based in San Francisco, and a resident company of the MBC BioLabs incubator.
$500K
$500K
United States
BusinessLatest roundTotal raisedDate- DeepSeq.AI
DeepSeq.AI, founded in 2019 and based in California, is an AI protein drug discovery company that combines high-throughput wet-lab assays with protein language models and generative AI to predict and optimize biologics properties (affinity, specificity, immunogenicity, PK, manufacturability) for large biopharma partners. It has DARPA and NSF funding, accelerator backing from Merck Digital Sciences Studio, StartX and SkyDeck, and investment from Illumina Ventures and Zaka VC.
$620K
$620K - Xaira Therapeutics
Integrated biotechnology applications involving artificial intelligence across the entire drug discovery and development process
Undisclosed · $1.0B · 2024-04
$1.0B - LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
— - ATLATL Innovation Center
ATLATL is a life-science innovation and shared-lab operator founded in 2017 in Shanghai's Zhangjiang, providing move-in-ready labs, on-site CRO services and R&D platforms (gene and cell therapy, AI-assisted drug screening, large-molecule research) to early-stage biotech companies across Shanghai, Beijing, Shenzhen, Hong Kong, Singapore and Australia.
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Bio Protocol
Funds and accelerates drug discovery through decentralized research agents
Seed · $7M · 2025-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - Miles Wang 新公司
Develops AI models for drug discovery
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.